Cargando…
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We as...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357427/ https://www.ncbi.nlm.nih.gov/pubmed/34391096 http://dx.doi.org/10.1016/j.ebiom.2021.103524 |
_version_ | 1783737128034762752 |
---|---|
author | Strengert, Monika Becker, Matthias Ramos, Gema Morillas Dulovic, Alex Gruber, Jens Juengling, Jennifer Lürken, Karsten Beigel, Andrea Wrenger, Eike Lonnemann, Gerhard Cossmann, Anne Stankov, Metodi V. Dopfer-Jablonka, Alexandra Kaiser, Philipp D. Traenkle, Bjoern Rothbauer, Ulrich Krause, Gérard Schneiderhan-Marra, Nicole Behrens, Georg M.N. |
author_facet | Strengert, Monika Becker, Matthias Ramos, Gema Morillas Dulovic, Alex Gruber, Jens Juengling, Jennifer Lürken, Karsten Beigel, Andrea Wrenger, Eike Lonnemann, Gerhard Cossmann, Anne Stankov, Metodi V. Dopfer-Jablonka, Alexandra Kaiser, Philipp D. Traenkle, Bjoern Rothbauer, Ulrich Krause, Gérard Schneiderhan-Marra, Nicole Behrens, Georg M.N. |
author_sort | Strengert, Monika |
collection | PubMed |
description | BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. FINDINGS: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. INTERPRETATION: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. FUNDING: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism. |
format | Online Article Text |
id | pubmed-8357427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83574272021-08-12 Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis Strengert, Monika Becker, Matthias Ramos, Gema Morillas Dulovic, Alex Gruber, Jens Juengling, Jennifer Lürken, Karsten Beigel, Andrea Wrenger, Eike Lonnemann, Gerhard Cossmann, Anne Stankov, Metodi V. Dopfer-Jablonka, Alexandra Kaiser, Philipp D. Traenkle, Bjoern Rothbauer, Ulrich Krause, Gérard Schneiderhan-Marra, Nicole Behrens, Georg M.N. EBioMedicine Research Paper BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. FINDINGS: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. INTERPRETATION: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. FUNDING: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism. Elsevier 2021-08-12 /pmc/articles/PMC8357427/ /pubmed/34391096 http://dx.doi.org/10.1016/j.ebiom.2021.103524 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Strengert, Monika Becker, Matthias Ramos, Gema Morillas Dulovic, Alex Gruber, Jens Juengling, Jennifer Lürken, Karsten Beigel, Andrea Wrenger, Eike Lonnemann, Gerhard Cossmann, Anne Stankov, Metodi V. Dopfer-Jablonka, Alexandra Kaiser, Philipp D. Traenkle, Bjoern Rothbauer, Ulrich Krause, Gérard Schneiderhan-Marra, Nicole Behrens, Georg M.N. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis |
title | Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis |
title_full | Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis |
title_fullStr | Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis |
title_full_unstemmed | Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis |
title_short | Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis |
title_sort | cellular and humoral immunogenicity of a sars-cov-2 mrna vaccine in patients on haemodialysis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357427/ https://www.ncbi.nlm.nih.gov/pubmed/34391096 http://dx.doi.org/10.1016/j.ebiom.2021.103524 |
work_keys_str_mv | AT strengertmonika cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT beckermatthias cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT ramosgemamorillas cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT dulovicalex cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT gruberjens cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT juenglingjennifer cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT lurkenkarsten cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT beigelandrea cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT wrengereike cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT lonnemanngerhard cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT cossmannanne cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT stankovmetodiv cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT dopferjablonkaalexandra cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT kaiserphilippd cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT traenklebjoern cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT rothbauerulrich cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT krausegerard cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT schneiderhanmarranicole cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis AT behrensgeorgmn cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis |